Menu

S. Van Bruwaene MD, PhD

Articles

Update in prostate cancer 2019

BJMO - volume 14, issue 1, january 2020

S. Van Bruwaene MD, PhD, P. Dirix MD, PhD, H. Van Poppel MD, PhD

SUMMARY

The prostate cancer (PCa) landscape has changed dramatically over the past few years. New paradigm-shifting data are published nearly every month. This review aims to give a brief overview of the most important publications of 2018–2019. From the ever-lasting discussion about PSA screening, with the recent publication of the CAP trial, over diagnostics where multi-parametric MRI has caused a true revolution, to hypofractionation in radiotherapy and the dramatic treatment shifts in metastatic hormone sensitive and non-metastatic castrate resistant PCa. All exciting data that will change clinical practice.

(BELG J MED ONCOL 2020;14(1):13–21)

Read more

P.03 THE TRITON CLINICAL TRIAL PROGRAMME: EVALUATION OF THE POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR RUCAPARIB IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY

BJMO - 12, issue 3, february 2018

B. Sautois MD, PhD, J.C. Goeminne MD, S. Rottey MD, PhD, D. Schrijvers MD, PhD, F. Van Aelst MD, S. Van Bruwaene MD, PhD, S. Watkins , A. Simmons , J. Go , M. Collins , T. Golsorkhi , W. Abida , C. Ryan , H. Scher , S. Chowdhury

Read more
Top